LogicBio Therapeutics has got off a $45 million series B funding round.
Australia’s Medibio reported promising results for a noninvasive diagnostic tool for post-traumatic stress disorder.
Neoantigen-based cancer vaccines represent new, truly personalized therapeutic approaches to treating cancer.
It’s time again to call on you to nominate your Fierce 15 for 2017.
Xenon and partner Teva’s experimental pain drug TV-45070 has missed all endpoints in patients with pain following shingles.
How PAREXEL's New Ecosystem of Technology, Processes and Expertise is Transforming Drug Development
New York City's bid to become a life sciences hotspot took another step forward this week with the help of a $5 million grant from the mayor's office.
Patrick Soon-Shiong's outfit NantCell will acquire Altor Bioscience for two bucks a share.
The third BioGeneration Ventures Fund has hit $74 million as it attracts new investors.
Mitoconix Bio has secured a $20 million series A round for its research work on neurological disorders
Digital diabetes management player Glooko raised $35 million to further develop its technology and expand in a number of markets.
Merck is mulling whether to file its CETP medication anacetrapib after posting some surprising positive topline data from the Reveal test.